To the best of our knowledge, our study is the first to evaluate the effect of 1,3,4-oxadiazole derivatives of pyrrolo[3,4-d]pyridazinone on the expression of Th17-specific transcription factors RORγt and STAT3 and the Th17 cell-polarizing cytokine IL-23 in an experimental colitis model, showing that pretreatment with these new compounds may prevent the increase in RORγt, STAT3, and IL-23 tissue levels. Here, STAT3 is linked to colitis.